Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Longevity Health Holdings Inc's Business Segments

Longevity Health Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of FY

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Elevai Skincare

38.4% of revenue

Total Revenue

$ 0

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/XAGE/segments                    

                        https://api.csimarket.com/api/v1/companies/XAGE/geographic                    

                        https://api.csimarket.com/api/v1/companies/XAGE/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - FY

Elevai Skincare38.4%

Revenue by Reportable Segment - FY

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Elevai Skincare	FY	$ 0	38.4%	-

Annual Results

Revenue Share by Reportable Segment - FY

Elevai Skincare38.4%

Revenue by Reportable Segment - FY

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Elevai Skincare	FY	$ 0	38.4%	-

Description of Longevity Health Holdings Inc

Longevity Health Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries operate in the health sector with a focus on regenerative medicine. The company was formerly known as Carmell Regen Med Corporation and, prior to that, Carmell Therapeutics Corporation until July 14, 2023. The company provides products and services related to health and regenerative medicine. Its Annual Report includes forward-looking statements regarding expected future growth, operating losses, future revenue, capital requirements, financing needs, and the ability to recruit and retain key personnel. These statements are based on current beliefs and expectations but are subject to risks and uncertainties that may cause actual results to differ materially. The company discusses its business operations, financial performance, market conditions, and efforts to commercialize its products and compete effectively.

The company operates as a single segment, which is managed and evaluated by the chief executive officer, the chief operating decision maker. This segment focuses on the development and commercialization of bio-aesthetic and bone and tissue healing products.